How to raise venture capital for a biotech, therapeutics, diagnostics, or medtech startup in 2026.
Biotech venture is a distinct discipline from software venture. Rounds are larger, tranched against clinical or preclinical milestones, and the investor set is a specialist community with its own diligence norms, board dynamics, and exit pathways (IPO, M&A by pharma, reverse merger).
Biotech companies don't build MVPs and iterate to product-market fit — they progress a preclinical or clinical asset (or a validated platform generating multiple assets) through defined regulatory milestones. Capital needs are $50M–$500M+ over the company's lifetime. Rounds are typically tranched, with subsequent tranches unlocked by hitting IND-enabling studies, Phase 1 readout, or Phase 2 readout.
Founders who understand biotech venture norms raise from the specialist community that owns the category. Founders who don't tend to waste a year pitching generalist software VCs who will not lead a therapeutics round.
Dedicated life sciences leaders: Flagship Pioneering, ARCH Venture Partners, Third Rock Ventures, Atlas Venture, Polaris Partners, Versant Ventures, MPM BioImpact, OrbiMed, RA Capital, RTW Investments, Deerfield, Perceptive Advisors, Bain Capital Life Sciences, and Sofinnova.
European specialists: Sofinnova Partners, Forbion, Medicxi, LSP (EQT Life Sciences), Gilde Healthcare, Kurma Partners, Andera Partners, Novo Holdings, Longwood Fund, and BioGeneration Ventures.
Corporate CVCs: Novartis Venture Fund, Pfizer Ventures, Lilly Ventures, GV (Google Ventures — heavy life sciences focus), MRL Ventures (Merck), Amgen Ventures, and Roche Venture Fund.
US: NIH grants (R01, R43/R44 SBIR/STTR) fund preclinical and early clinical work at $150K–$3M+. CIRM (California) funds stem cell and regenerative medicine at $1M–$20M+. BARDA funds biodefense and pandemic preparedness. CDMRP (DOD) funds cancer, PTSD, and rare disease research.
European: EIC Accelerator (up to €2.5M grant + €15M equity), Innovate UK Biomedical Catalyst, Horizon Europe collaborative grants, and national programs (Bpifrance Deeptech, KfW, Vinnova). Philanthropy: Wellcome Leap, CZI (Chan Zuckerberg Initiative), Gates Foundation, and disease-specific foundations (CF Foundation, JDRF, Michael J. Fox Foundation).
UK: ARIA (Advanced Research and Invention Agency) funds high-risk biotech under specific programme directors.
A typical Series A therapeutics round is $50M–$100M+ committed but drawn in tranches: an initial $15M–$30M at close, subsequent tranches unlocked by IND-enabling studies, IND filing, Phase 1a readout, and Phase 1b readout. Each tranche is priced at the same round terms unless the syndicate agrees to re-price.
Tranching protects investors from binary risk and protects founders from having to run a new round after a single negative readout. It also means the effective dilution per milestone is significantly lower than a naive comparison to software Series A dilution suggests.
Asset companies advance one or two therapeutic candidates through the clinic — capital-efficient, faster to a meaningful readout, and the standard model for most Series A therapeutics companies. Platform companies (Moderna, Recursion, Insitro-style) invest in a technology that generates many potential assets — larger rounds, longer timelines, and higher valuations if the platform validates.
Investors evaluate platforms on multi-asset generation (has the platform produced 3+ credible development candidates?), transferability (do external partners want to license?), and asset progression (is at least one asset in the clinic?). Platforms that don't generate assets by Series B are typically de-rated to asset-company valuations.
Pitching generalist software VCs — most will not lead a therapeutics round. Focus on the ~50 dedicated life sciences funds that own the category. Skipping NIH grants — SBIR/STTR grants fund preclinical work with zero dilution and materially improve Series A positioning. Under-tranching — a fully-drawn $60M Series A without milestone gates gives away future negotiating leverage. Under-investing in scientific advisors — biotech Series A leads want to see 5–10 credible KOLs (key opinion leaders) actively engaged, not just listed on a slide.
Investor directory · Fundraising library · Articles A–Z · Company funding database